AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33186192 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy
Number of subjects: 50
Study 33186192 — intervention group
Group type: COMPARATOR
Intervention: Office-based placebo therapy
Number of subjects: 50
Study 33805664 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention (12 weekly sessions of 90 min)
Number of subjects: 380
Study 33805664 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 380
Study 33368978 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced video
Number of subjects: 54
Study 33368978 — intervention group
Group type: COMPARATOR
Intervention: Non-enhanced video
Number of subjects: 54
Study 33033007 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention for HIV knowledge
Number of subjects: 662
Study 34003449 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative 5th month
Number of subjects: 50
Study 34003449 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative 5th month
Number of subjects: 50
Study 34170910 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive practices (wearing facemask, frequent hand washing)
Number of subjects: 1134
Study 34170910 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk of COVID-19
Number of subjects: 1134
Study 34170910 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk to family
Number of subjects: 1134
Study 34170910 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry score about COVID-19 crisis
Number of subjects: 1134
Study 34170910 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry about health system overwhelmed
Number of subjects: 1134
Study 34170910 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry about health of loved ones
Number of subjects: 1134
Study 34170910 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry about losing someone due to COVID-19
Number of subjects: 1134
Study 34170910 — intervention group
Group type: COMPARATOR
Intervention: Previous clinical care experience
Number of subjects: 1134
Study 32813737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense BGN
Number of subjects: 24
Study 32813737 — intervention group
Group type: EXPERIMENTAL
Intervention: MBGN
Number of subjects: 24
Study 32813737 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study 32813737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense BGN and MBGN
Number of subjects: 24
Study 35172592 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS+VR‐JIT
Number of subjects: 90
Study 35172592 — intervention group
Group type: COMPARATOR
Intervention: IPS as usual
Number of subjects: 90
Study 33096965 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity-interval-training exercise with blood flow restriction (BFR) and body cooling (BC)
Number of subjects: 25
Study 33096965 — intervention group
Group type: COMPARATOR
Intervention: Exercise without blood flow restriction (BFR) and body cooling (BC)
Number of subjects: 25
Study 32700009 — intervention group
Group type: COMPARATOR
Intervention: Nonabsorbable sutures (6/0 polypropylene)
Number of subjects: 64
Study 32700009 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures (6/0 polyglytone 6211)
Number of subjects: 64
Study 33009239 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stem (n = 56)
Number of subjects: 100
Study 33009239 — intervention group
Group type: COMPARATOR
Intervention: Standard stem (n = 44)
Number of subjects: 100
Study 32000509 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Child Health intervention (randomized controlled trial)
Number of subjects: 30
Study 32000509 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Child Health intervention (quasi-experimental study)
Number of subjects: 30
Study 36194220 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan plus exercise
Number of subjects: 114
Study 36194220 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan plus attention control
Number of subjects: 114
Study 36194220 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus exercise
Number of subjects: 114
Study 36194220 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus attention control
Number of subjects: 114
Study 36194220 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 114
Study 36194220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 34695957 — intervention group
Group type: EXPERIMENTAL
Intervention: S2 prototype (interactive grasp rehabilitation system)
Number of subjects: 26
Study 34695957 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 26
Study 33355155 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn 2 Learn (B2L) intervention
Number of subjects: 670
Study 33355155 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 670
Study 36361335 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (60 min sessions, 3 days/week, from the 17th gestational week until birth)
Number of subjects: 85
Study 36361335 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of fruits
Number of subjects: 85
Study 36361335 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intake of red meat and subproducts
Number of subjects: 85
Study 36361335 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater Mediterranean diet adherence
Number of subjects: 85
Study 33863326 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated eDiagnosis Approach (IeDA)
Number of subjects: 10
Study 33863326 — intervention group
Group type: COMPARATOR
Intervention: Control (standard IMCI)
Number of subjects: 10
Study 35109752 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN) of thenar muscles TrP(s)
Number of subjects: 30
Study 35109752 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 30
Study 33465135 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 9508
Study 33465135 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful fibrinolysis
Number of subjects: 9508
Study 33465135 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful fibrinolysis
Number of subjects: 9508
Study 33465135 — intervention group
Group type: COMPARATOR
Intervention: CKD status
Number of subjects: 9508
Study 32843171 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude rehabilitation (HA, 3100 m)
Number of subjects: 50
Study 32843171 — intervention group
Group type: COMPARATOR
Intervention: Low altitude rehabilitation (LA, 760 m)
Number of subjects: 50
Study 35147680 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome monotherapy (40 mg/kg intravenous liposomal amphotericin B administered in 8 equal doses over 24 days)
Number of subjects: 150
Study 35147680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (30 mg/kg intravenous AmBisome administered in 6 equal doses over 24 days + 1.4 g oral miltefosine administered in 2 daily doses of 50 mg over 14 days)
Number of subjects: 150
Study 33446902 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-5 sessions of ALSS therapy
Number of subjects: 601
Study 33446902 — intervention group
Group type: COMPARATOR
Intervention: 1-2 sessions of ALSS therapy
Number of subjects: 601
Study 33446902 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥6 sessions of ALSS therapy
Number of subjects: 601
Study 33446902 — intervention group
Group type: COMPARATOR
Intervention: ≤2 sessions of ALSS therapy
Number of subjects: 601
Study 32841256 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplement
Number of subjects: 259
Study 32841256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 34059932 — intervention group
Group type: EXPERIMENTAL
Intervention: pirenzepine 75 mg
Number of subjects: 11
Study 34059932 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 10 mg
Number of subjects: 11
Study 34059932 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 10 mg plus pirenzepine 75 mg
Number of subjects: 11
Study 34059932 — intervention group
Group type: COMPARATOR
Intervention: vonoprazan 10 mg alone (control)
Number of subjects: 11
Study 35219331 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 12 weeks
Number of subjects: 187
Study 35219331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 32192515 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 0
Study 32192515 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34043794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual hormone clamp (cortisol and testosterone fixed)
Number of subjects: 34
Study 34043794 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (cortisol and testosterone not fixed)
Number of subjects: 34
Study 33068901 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week group exercise and self-management intervention facilitated by a physiotherapist
Number of subjects: 349
Study 33068901 — intervention group
Group type: COMPARATOR
Intervention: Continued GP management
Number of subjects: 349
Study 34473247 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of familism in African American and Hispanic participants compared to Whites.
Number of subjects: 243
Study 34473247 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater levels of social support in African Americans compared to Whites.
Number of subjects: 243
Study 34473247 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analyses of familism and self-efficacy.
Number of subjects: 243
Study 34473247 — intervention group
Group type: EXPERIMENTAL
Intervention: Familism in the Hispanic subgroup.
Number of subjects: 243
Study 34704984 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g amoxicillin 1 hour prior to surgery
Number of subjects: 154
Study 34704984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 33327134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal network algorithm for mapping images into networks
Number of subjects: 0
Study 33091856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon Patch (CP)
Number of subjects: 66
Study 33091856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 34031921 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantoplasty with cyclic loading
Number of subjects: 30
Study 34031921 — intervention group
Group type: COMPARATOR
Intervention: Non-instrumented controls
Number of subjects: 30
Study 34031921 — intervention group
Group type: EXPERIMENTAL
Intervention: All implants (instrumented and non-instrumented)
Number of subjects: 30
Study 32238855 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) with 100% oxygen at 30-70 litres/min
Number of subjects: 60
Study 32238855 — intervention group
Group type: COMPARATOR
Intervention: Facemask oxygenation with 100% oxygen at 10 litres/min
Number of subjects: 60
Study 32238855 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE
Number of subjects: 60
Study 32238855 — intervention group
Group type: COMPARATOR
Intervention: THRIVE and facemask
Number of subjects: 60
Study 35689170 — intervention group
Group type: EXPERIMENTAL
Intervention: Om chanting and Yoga Nidra for five days a week for two months
Number of subjects: 80
Study 35689170 — intervention group
Group type: COMPARATOR
Intervention: Regular conventional medications
Number of subjects: 80
Study 34144104 — intervention group
Group type: EXPERIMENTAL
Intervention: Home systolic BP
Number of subjects: 97
Study 34144104 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular mass index (LVMI)
Number of subjects: 97
Study 32195950 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 30
Study 32195950 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir and simulated PDT treatment (control)
Number of subjects: 30
Study 34577231 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI simulator
Number of subjects: 60
Study 34577231 — intervention group
Group type: COMPARATOR
Intervention: Traditional educational method (lectures)
Number of subjects: 60
Study 36456740 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure therapy (PPT) combined with medications, duration of 8 months.
Number of subjects: 52
Study 36456740 — intervention group
Group type: COMPARATOR
Intervention: Medications alone (Control group), n=26.
Number of subjects: 52
Study 36456740 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure therapy (PPT) combined with medications.
Number of subjects: 52
Study 35932518 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised UL virtual reality exercises (ULVRE)
Number of subjects: 45
Study 35932518 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-supervised UL virtual reality exercises (ULVRE)
Number of subjects: 45
Study 35932518 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional rehabilitation exercises)
Number of subjects: 45
Study 35564846 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-related training and case manager support
Number of subjects: 180
Study 35096601 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Needle Biopsy (CNB)
Number of subjects: 84
Study 35096601 — intervention group
Group type: COMPARATOR
Intervention: Fine Needle Aspiration (FNA)
Number of subjects: 84
Study 36192552 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg volagidemab
Number of subjects: 79
Study 36192552 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg volagidemab
Number of subjects: 79
Study 36192552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 32556585 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral laminotomy with crossover (UL)
Number of subjects: 437
Study 32556585 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral laminotomy (BL)
Number of subjects: 437
Study 32556585 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinous process osteotomy (SPO)
Number of subjects: 437
Study 36341835 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min HIIE
Number of subjects: 40
Study 36341835 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min MICE
Number of subjects: 40
Study 36341835 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min HIIE
Number of subjects: 40
Study 36341835 — intervention group
Group type: COMPARATOR
Intervention: Reading control intervention
Number of subjects: 40
Study 36122501 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentil-based meals (300 g)
Number of subjects: 30
Study 36122501 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentil-based meals (600 g)
Number of subjects: 30
Study 36122501 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g lentils)
Number of subjects: 30
Study 36122501 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentil-based meals (300 g and 600 g)
Number of subjects: 30
Study 34235222 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed AFO with Somos NeXt
Number of subjects: 15
Study 34235222 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed AFO with PA12
Number of subjects: 15
Study 35092891 — intervention group
Group type: EXPERIMENTAL
Intervention: TPTD 20 μg daily for an average of 6.1 weeks
Number of subjects: 0
Study 35092891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 35092891 — intervention group
Group type: EXPERIMENTAL
Intervention: TPTD 20 μg daily
Number of subjects: 0
Study 32554035 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer network-based feedback program
Number of subjects: 163
Study 34890537 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg dose of CoronaVac, administered as a primary third dose 2 months after the second dose (cohort 1a-14d-2m)
Number of subjects: 600
Study 34890537 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg dose of CoronaVac, administered as a booster dose 8 months after the second dose (cohort 1b-14d-8m)
Number of subjects: 600
Study 34890537 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg dose of CoronaVac, administered as a booster dose 8 months after the second dose (cohort 2b-28d-8m)
Number of subjects: 600
Study 34890537 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg dose of CoronaVac, administered as a primary third dose 2 months after the second dose (cohort 2a-28d-2m)
Number of subjects: 600
Study 34890537 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 μg, 3 μg, or 6 μg doses of CoronaVac, administered as a third dose 8 months after the second dose in adults aged 60 years and older
Number of subjects: 600
Study 34890537 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 600
Study 33936066 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher circulating levels of IL‐2Rα
Number of subjects: 0
Study 33936066 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating IL‐1Ra
Number of subjects: 0
Study 33936066 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ILs
Number of subjects: 0
Study 35679283 — intervention group
Group type: EXPERIMENTAL
Intervention: JITAI group (personalized just‐in‐time adaptive intervention)
Number of subjects: 240
Study 35679283 — intervention group
Group type: COMPARATOR
Intervention: Control group (Fitbit® without personalized feedback)
Number of subjects: 240
Study 33818442 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine (40 mL/0.5%) + dexmedetomidine (1 μg/kg)
Number of subjects: 105
Study 33818442 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine (40 mL/0.5%) + fentanyl (1 μg/kg)
Number of subjects: 105
Study 33818442 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine (40 mL/0.5%) + verapamil (2.5 mg)
Number of subjects: 105
Study 32301412 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety behaviours (SBs)
Number of subjects: 111
Study 32301412 — intervention group
Group type: COMPARATOR
Intervention: No safety behaviours (control)
Number of subjects: 111
Study 32301412 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (SBs and no SBs)
Number of subjects: 111
Study 33220526 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-minute withdrawal time
Number of subjects: 1027
Study 33220526 — intervention group
Group type: COMPARATOR
Intervention: 6-minute withdrawal time
Number of subjects: 1027
Study 33476571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b (100 μg subcutaneously every 2 weeks) on top of phlebotomy and low-dose aspirin (100 mg daily)
Number of subjects: 127
Study 33476571 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy (300 mL per session to maintain haematocrit <45%) and low-dose aspirin (100 mg daily)
Number of subjects: 127
Study 35686634 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (2000 mg) plus 400 μg folic acid daily from 14-24 gestational weeks
Number of subjects: 60
Study 35686634 — intervention group
Group type: COMPARATOR
Intervention: Control group (400 μg of folic acid daily from 14-24 gestational weeks)
Number of subjects: 60
Study 32568134 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP = 5 cm H2O (group P)
Number of subjects: 40
Study 32568134 — intervention group
Group type: COMPARATOR
Intervention: PEEP = 0 cm H2O (group C)
Number of subjects: 40
Study 36153034 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 0
Study 36153034 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral acupuncture
Number of subjects: 0
Study 36153034 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 33657259 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment (n = 31)
Number of subjects: 63
Study 33657259 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone acetate ointment (n = 32)
Number of subjects: 63
Study 32643359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO)
Number of subjects: 61
Study 32643359 — intervention group
Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 61
Study 36195945 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (containing Lactobacillus, Bifidobacterium, Streptococcus, and fructooligosaccharides)
Number of subjects: 42
Study 36195945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 36195945 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 42
Study 34702331 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamics and comprehensive clinical assessment
Number of subjects: 1096
Study 34702331 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive clinical assessment only
Number of subjects: 1096
Study 32944407 — intervention group
Group type: EXPERIMENTAL
Intervention: SVILE regimen
Number of subjects: 103
Study 32944407 — intervention group
Group type: COMPARATOR
Intervention: P-GemOx regimen
Number of subjects: 103
Study 35100429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (NIC) 21 mg, daily
Number of subjects: 35
Study 35100429 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (PBO)
Number of subjects: 35
Study 35100429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (NIC)
Number of subjects: 35
Study 34427556 — intervention group
Group type: EXPERIMENTAL
Intervention: JBS3 lifetime risk calculator
Number of subjects: 173
Study 34427556 — intervention group
Group type: COMPARATOR
Intervention: QRISK2 10-year risk calculator
Number of subjects: 173
Study 33306247 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA treatment for <4 weeks in patients with F0-F3 liver fibrosis
Number of subjects: 365
Study 33306247 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA treatment for <8 weeks in patients with liver cirrhosis
Number of subjects: 365
Study 33079022 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic virus B (GarV-B) detection using RT-PCR and ELISA
Number of subjects: 5
Study 33079022 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing of 30 garlic germplasm accessions for GarV-B using RT-PCR
Number of subjects: 5
Study 35694835 — intervention group
Group type: EXPERIMENTAL
Intervention: casein phosphopeptide‐amorphous calcium fluoride phosphate (CPP‐ACFP)
Number of subjects: 40